Loading organizations...
Key people at Lumenis.
Lumenis was founded in 1966 by Shimon Eckhouse (Founder, chairman and CEO).
Lumenis develops and commercializes advanced energy-based medical technologies, establishing itself as a global leader in the field. The company specializes in systems utilizing intense pulsed light (IPL), radio frequency (RF), and various laser technologies, including Holmium and CO2. These innovations are engineered to deliver minimally invasive solutions across a range of medical and aesthetic applications.
The company was founded in Israel in 1966, stemming from an early recognition of the transformative medical potential inherent in laser and light technologies. This foundational insight drove the development of devices that could safely and effectively treat various conditions, pioneering the application of energy-based solutions within clinical practice.
Lumenis serves practitioners and patients within the aesthetic and vision markets, providing solutions that address diverse therapeutic and cosmetic needs. The company's long-term vision centers on continuously advancing medical care by expanding the capabilities of energy-based technologies, aiming to improve patient outcomes and enhance quality of life through innovative treatment options.
Lumenis was founded in 1966 by Shimon Eckhouse (Founder, chairman and CEO).
Lumenis is a global leader in minimally invasive clinical solutions for surgical, ophthalmic, and aesthetic markets, specializing in energy-based technologies like lasers, intense pulsed light (IPL), and radio-frequency (RF) systems.[1][2][3] It develops products for medically necessary treatments (e.g., glaucoma, retinal conditions) and elective procedures, serving clinics and hospitals worldwide with an installed base exceeding 80,000 systems across over 100 countries.[1][2][3] The company solves critical healthcare challenges by enabling precise, non-invasive therapies—such as Selective Laser Trabeculoplasty (SLT) for glaucoma with a 93% success rate—and drives growth through over 270 patents, 100+ FDA clearances, and partnerships with key opinion leaders (KOLs).[1][2]
Founded in 1966, Lumenis pioneered laser-based medical treatments, becoming the first company to commercially introduce a laser product for retinal conditions.[1][2] Its early innovations included solutions for anterior and posterior eye segments, addressing issues like diabetic retinopathy, retinal detachment, glaucoma, and secondary cataracts.[1] By 1991, it had established a strong global presence, evolving over nearly 60 years to set technological gold standards in ophthalmology, surgery, and aesthetics through continuous R&D and expansions like the Array LaserLink for efficient retinal pattern scanning.[1][2][3]
Lumenis rides the wave of advancing minimally invasive medical technologies, capitalizing on rising demand for precise, outpatient energy-based treatments amid aging populations and chronic eye diseases like glaucoma and diabetic retinopathy.[1] Its timing aligns with healthcare shifts toward non-surgical options, fueled by market forces such as expanding aesthetic procedures and regulatory approvals (e.g., FDA clearances).[2] By influencing standards—through innovations like SLT and pattern scanning lasers—Lumenis shapes ophthalmology and aesthetics ecosystems, enabling faster procedures and better outcomes that reduce hospital burdens globally.[1][2]
Lumenis is poised for sustained growth by leveraging its patent portfolio and global footprint to expand into emerging ophthalmic diagnostics and next-gen RF/IPL hybrids.[1][2] Trends like AI-enhanced laser precision and personalized medicine will amplify its edge, potentially boosting adoption in underserved markets. Its influence may evolve toward dominating integrated eye care platforms, reinforcing its legacy as a trailblazer in energy-based clinical innovation.[1][3]
Key people at Lumenis.
